FDC Limited

FDC

INE258B01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:54 2024-07-12 am EDT			5-day change	1st Jan Change
489.8 ^INR	-2.03%		-4.93%	+23.67%

May. 29	FDC Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
May. 02	FDC Limited Announces Board Completion of Tenure of Independent Directors	CI

FDC Limited Grants ANDA Approval by United States Food and Drug Administration for Ofloxacin Otic Solution, 0.3%

January 21, 2022 at 08:54 am EST

FDC Limited announced that, the Company has been granted ANDA approval by United States Food and Drug Administration (U.S. FDA), for Ofloxacin Otic Solution, 0.3%.

Latest news about FDC Limited

FDC Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 29	CI
FDC Limited Announces Board Completion of Tenure of Independent Directors	May. 02	CI
FDC Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 07	CI
FDC Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 08	CI
Tranche Update on FDC Limited's Equity Buyback Plan announced on August 9, 2023.	23-09-15	CI
Carrefour sticks price warnings on food to shame suppliers	23-09-14	RE
FDC Limited's Equity Buyback announced on August 9, 2023, has closed with 3,100,000 shares, representing 1.87% for INR 1,550 million.	23-09-05	CI
FDC Limited announces an Equity Buyback for 3,100,000 shares, representing 1.87% for INR 1,550 million.	23-08-09	CI
FDC Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-09	CI
FDC Limited agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA Ltd. from other existing shareholders.	23-08-08	CI
FDC Limited authorizes a Buyback Plan.	23-08-08	CI
FDC Board to Consider Buyback of Shares	23-08-03	MT
FDC Limited's Board intends to launch an Equity Buyback on August 9, 2023	23-08-03	CI
FDC Limited's Board intends to launch an Equity Buyback on August 9, 2023.	23-08-02	CI
FDC Gets Establishment Inspection Report from US FDA for Raigad, India Manufacturing Unit	23-06-15	MT
FDC Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-25	CI
FDC Names New CFO	23-04-06	MT
FDC Limited Appoints Executive Changes	23-04-06	CI
FDC's Consolidated Profit Climbs in Fiscal Q3	23-02-10	MT
FDC Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09	CI
FDC's Consolidated Profit Drops in Fiscal Q2	22-11-15	MT
FDC Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent Director	22-09-23	CI
FDC Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-04	CI
FDC Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22-05-25	CI

FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FDC LIMITED	+23.67%	955M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals

FDC Limited

Equities

FDC

INE258B01022

Pharmaceuticals

FDC Limited Grants ANDA Approval by United States Food and Drug Administration for Ofloxacin Otic Solution, 0.3%

Latest news about FDC Limited

Chart FDC Limited

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals